Γ

SynBioBeta Speaker

Scott Fay

Ansa Biotechnologies

VP Informatics

Scott Fay leads the design, development, and support of software systems that power Ansa’s enzymatic DNA synthesis platform. Since joining the company in 2022, he has overseen the development of Ansa’s manufacturing execution system, encompassing LIMS, work order orchestration, quality control, biosecurity screening, sample packaging management, and integrated manufacturing and R&D analytics.

Sessions Featuring

Scott

This Year

Main Stage Panel

2:00 PM

-

2:30 PM

Business of Biology

The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense in Programmable Biology

As AI, automation, and scalable biotechnologies accelerate the design and deployment of biology, the line between innovation and risk is increasingly blurred. This session explores how advances in programmable biology are reshaping biosecurity and biodefense, from dual-use risks and supply-chain vulnerabilities to new models for detection, governance, and defense. Leaders from industry, government, and research will discuss how to responsibly accelerate biology while protecting public health and national security.

Main Stage Panel

2:00 PM

-

2:30 PM

Business of Biology

The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense in Programmable Biology

As AI, automation, and scalable biotechnologies accelerate the design and deployment of biology, the line between innovation and risk is increasingly blurred. This session explores how advances in programmable biology are reshaping biosecurity and biodefense, from dual-use risks and supply-chain vulnerabilities to new models for detection, governance, and defense. Leaders from industry, government, and research will discuss how to responsibly accelerate biology while protecting public health and national security.

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include